NSLEEVE: Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04626232
Collaborator
(none)
144
1
2
42
3.4

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the impact of the procedure (sleeve gastrectomy technique with a Nissen fundoplication (N-Sleeve) vs conventional sleeve gastrectomy technique

Condition or Disease Intervention/Treatment Phase
  • Procedure: N-SLEEVE technique
  • Procedure: SLEEVE
N/A

Detailed Description

Bariatric surgery is recognized as the only effective therapeutic weapon for morbidly obese patients. Gastro-Oesophageal Reflux Disease is very common (30-45% of cases) with serious consequences on the oesophageal mucosa. It could be an exacerbation of preoperative GERD symptoms or a "de novo" postoperative GERD. Medical treatment is usually effective but reoperation may be required to treat refractory GERD.GERD can lead to serious consequences on the oesophageal mucosa (esophagitis, Barrett's oesophagus, cancer). The conventional surgical treatment of GERD is fundoplication, which can be partial or total. The gastric fundus is wrapped around the oesophagus to strengthen the tone of the oesophageal sphincter. We hypothesize that the creation of a total anti-reflux fundoplication before performing LSG (Nissen + Sleeve = N-sleeve) could significantly reduce the postoperative GERD complication as compared with the standard LSG.

To evaluate the impact of the procedure N-Sleeve vs conventional sleeve gastrectomy technique on the rate of patient with GERD at 1, 6 and 12 months postoperatively. To evaluate the impact of the procedure (sleeve gastrectomy technique with a Nissen fundoplication (N-Sleeve) vs conventional sleeve gastrectomy technique during all the follow-up on the gastric fistula on the staple line, on the postoperative morbidity and mortality , on the evolution of weight loss, the excess weight loss, the BMI and the excess BMI loss during the follow-up. Evaluate the impact of these procedures on the quality of life of patients at baseline and 1, 6 and 12 months postoperatively. Evaluate the safety during all the follow-up.

•Methods: Monocentric, randomized, single-blind controlled trial, with 2 parallel arms. 144 patients. The target population is all adult patients with severe or morbid obesity, who underwent multidisciplinary care and having the criteria of 2009 HAS recommendations for bariatric surgery.

Presence of gastro-oesophageal reflux will be assessed by a composite criteria: consumption of Proton Pump Inhibitor and gastroscopy at baseline and 12-month.

The N-SLEEVE technique consists of creating a gastric total fundoplication before to perform the removal of 2/3 of the stomach.

This study may really lead to a change in terms of choice of first intention bariatric procedures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Monocentric Prospective Randomized Controlled Study Comparing the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique (N-Sleeve) in Morbidly Obese Patients
Anticipated Study Start Date :
Jan 5, 2021
Anticipated Primary Completion Date :
Jul 5, 2023
Anticipated Study Completion Date :
Jul 5, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: N SLEEVE

Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).

Procedure: N-SLEEVE technique
The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).

Other: SLEEVE

The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.

Procedure: SLEEVE
SLEEVE Technique : Removal of 2/3 of the stomach

Outcome Measures

Primary Outcome Measures

  1. Presence of gastroesophageal reflux disease [12 months]

    Gastroscopy is a standard endoscopic examination that examines the lining of the oesophagus and stomach. It can detect Helicobacter pylori and highlight the presence of: Gastro-Oesophageal Reflux Disease Gastritis Esophagitis Barrett's oesophagus Hiatal hernia Gastric tumor Bile reflux Incompetent cardia

  2. Consumption of Proton Pump Inhibitor [12 months]

    The consumption of PPI, revealing the presence of GERD symptoms, will be recorded at each visit thanks a diary card.

Secondary Outcome Measures

  1. type of fistula Month 1 [Month 1]

    The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.

  2. severity of fistula Month 1 [Month 1]

    The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)

  3. type of fistula Month 6 [Month 6]

    The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.

  4. severity of fistula Month 6 [Month 6]

    The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)

  5. type of fistula Month 12 [Month 12]

    The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.

  6. severity of fistula Month 12 [Month 12]

    The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)

  7. Postoperative morbidity Month 1 [Month 1]

    Assessed by the type of postoperative complication

  8. Postoperative morbidity Month 6 [Month 6]

    Assessed by the frequency of each type of postoperative complication

  9. Postoperative morbidity Month 12 [Month 12]

    Assessed by the severity of each type of postoperative complication

  10. Weight loss Month 1 [Month 1]

    The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.

  11. Weight loss Month 6 [Month 6]

    The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.

  12. Weight loss Month 12 [Month 12]

    The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.

  13. mortality Month 1 [Month 1]

    number of death

  14. mortality Month 6 [Month 6]

    number of death

  15. mortality Month 12 [Month 12]

    number of death

  16. Quality of Life Month 1 : SF 12 [Month 1]

    Quality of life will be assessed by the self-questionnaire SF12

  17. Quality of Life Month 6 : SF 12 [Month 6]

    Quality of life will be assessed by the self-questionnaire SF12

  18. Quality of Life Month 12 : SF 12 [Month 12]

    Quality of life will be assessed by the self-questionnaire SF12

  19. Serious adverse event Month 1 [Month 1]

    number and type of adverse events

  20. safety Month 6: number and type of adverse events [Month 6]

    number and type of adverse events

  21. safety Month 12: number and type of adverse events [Month 12]

    number and type of adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Signed informed consent form

  • Subjects must be able to attend all scheduled visits and to comply with all trial procedures

  • Subjects must be covered by public health insurance

  • Contraception efficacy

  • Subjects eligible for sleeve gastrectomy after multidisciplinary evaluation according to HAS 2009 criteria: BMI ≥ 40 kg / m² with failure of the dietary treatment for at least 1 year, or a BMI ≥ 35kg / m² with at least one co-morbidity that could be improved after surgery (hypertension, obstructive sleep apnea hypopnea syndrome (OSAHS) and other severe respiratory disorders, severe metabolic disorders (especially type 2 diabetes), debilitating musculoskeletal diseases, non-alcoholic steato-hepatitis (NASH))

Exclusion Criteria:
  • Subject unable to read or/and write

  • Planned longer stay outside the region that prevents compliance with the visit plan

  • Current pregnancy

  • Previous bariatric surgery (ring, vertical banded gastroplasty, sleeve gastrectomy or Gastric Bypass).

  • BMI > 50 kg / m² for women and > 45kg / m² for men (dissecting the hiatus region can be a technical challenge in these cases).

  • Barrett oesophagus and esophagitis stage III and IV.

  • Funditis

  • Long-term NSAIDs and/or corticosteroid therapy

  • No affiliation at the French social security scheme.

  • Major protected by law.

  • Deprivation of liberty by judicial or administrative decision.

  • Participation to another clinical research program.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Montpellier Montpellier France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT04626232
Other Study ID Numbers:
  • RECHMPL20-0013 PROM 7925
First Posted:
Nov 12, 2020
Last Update Posted:
Nov 12, 2020
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 12, 2020